Regeneron Pharmaceuticals Inc. (REGN) has announced promising three-year data from an extension study of the Phase 3 PHOTON trial for its EYLEA HD (aflibercept) Injection 8 mg, targeting patients with diabetic macular edema (DME).
The study's findings at the three-year mark reveal that a significant majority of patients maintained the visual benefits and anatomical enhancements obtained by the study's end at two years. Additionally, these patients benefited from extended intervals between treatments, surpassing previously observed durations.
Importantly, those transitioned to EYLEA HD exhibited notably slower fluid reaccumulation after their initial dose. This outcome, along with the extended dosing intervals, underscores EYLEA HD’s prolonged effectiveness.
In week 156 of the Phase 3 PHOTON trial extension, 88% of the participants on EYLEA HD maintained dosing intervals of 12 weeks or more, all while preserving the visual and anatomical improvements achieved during the first 96 weeks.
